Ebola virus: unravelling pathogenesis to combat a deadly disease
- PMID: 16616875
- DOI: 10.1016/j.molmed.2006.03.006
Ebola virus: unravelling pathogenesis to combat a deadly disease
Abstract
Ebola virus (EBOV) causes severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus. Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease. Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction. Here, we attempt to summarize the current knowledge on EBOV pathogenesis focusing on these two factors and on recent progress in the development of vaccines and potential therapeutics.
Similar articles
-
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.J Virol. 2006 Mar;80(6):2738-46. doi: 10.1128/JVI.80.6.2738-2746.2006. J Virol. 2006. PMID: 16501083 Free PMC article.
-
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions.Expert Rev Mol Med. 2004 Sep 21;6(20):1-24. doi: 10.1017/S1462399404008300. Expert Rev Mol Med. 2004. PMID: 15383160 Review.
-
Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8. doi: 10.1016/j.cimid.2007.05.005. Epub 2007 Jul 3. Comp Immunol Microbiol Infect Dis. 2007. PMID: 17610952 Review.
-
Experimental Respiratory Infection of Marmosets (Callithrix jacchus) With Ebola Virus Kikwit.J Infect Dis. 2015 Oct 1;212 Suppl 2:S336-45. doi: 10.1093/infdis/jiv371. Epub 2015 Jul 23. J Infect Dis. 2015. PMID: 26209682
-
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7. doi: 10.1086/520583. J Infect Dis. 2007. PMID: 17940980
Cited by
-
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13. J Virol. 2013. PMID: 23408633 Free PMC article.
-
Antiviral Activity Exerted by Natural Products against Human Viruses.Viruses. 2021 May 4;13(5):828. doi: 10.3390/v13050828. Viruses. 2021. PMID: 34064347 Free PMC article. Review.
-
Ebolavirus Database: Gene and Protein Information Resource for Ebolaviruses.Adv Bioinformatics. 2016;2016:1673284. doi: 10.1155/2016/1673284. Epub 2016 Apr 14. Adv Bioinformatics. 2016. PMID: 27190508 Free PMC article.
-
Therapeutic strategies to target the Ebola virus life cycle.Nat Rev Microbiol. 2019 Oct;17(10):593-606. doi: 10.1038/s41579-019-0233-2. Epub 2019 Jul 24. Nat Rev Microbiol. 2019. PMID: 31341272 Review.
-
Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry.Virol J. 2013 Nov 9;10:331. doi: 10.1186/1743-422X-10-331. Virol J. 2013. PMID: 24209904 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical